Phio Pharmaceuticals (PHIO) Cash from Investing Activities (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Cash from Investing Activities came in at $3000.0 in Q1 2026, up 250.0% YoY from $857.14 in Q1 2025, and up 142.86% on a QoQ basis from -$7000.0 in Q3 2025.
Phio Pharmaceuticals (PHIO) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Cash from Investing Activities data on file, last reported at $3000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 250.0% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7000.0 (down 216.67% YoY) and the FY2025 annual result came in at -$12000.0, down 250.0% from the prior year.
- Cash from Investing Activities grew to $3000.0 in Q1 2026, from -$7000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $8000.0 in Q4 2024 to a low of -$104000.0 in Q1 2022.
- A 5-year average of -$14111.1 and a median of -$5000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 1633.33% — and 2026, when it jumped 250.0%.
- Tracing PHIO's Cash from Investing Activities over 5 years: stood at -$7000.0 in 2022, then gained by 28.57% to -$5000.0 in 2023, then surged by 260.0% to $8000.0 in 2024, then tumbled by 187.5% to -$7000.0 in 2025, then surged by 142.86% to $3000.0 in 2026.
- The last three Cash from Investing Activities figures came in at $3000.0 (Q1 2026), -$7000.0 (Q3 2025), and -$3000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Phio Pharmaceuticals | 13.77 Mn | 13.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Sep 30, 2022 | -7,000.00 |
| Sep 30, 2022 | -7,000.00 |
| Jun 30, 2022 | -10,000.00 |
| Jun 30, 2022 | -10,000.00 |
| Mar 31, 2022 | -104,000.00 |
| Mar 31, 2022 | -104,000.00 |
| Sep 30, 2021 | -30,000.00 |
| Sep 30, 2021 | -30,000.00 |